Continuing Pharmacy Education / CE Master List / Load-Bearing Walls: Getting Cardiovascular Therapy Right the First Time -RECORDED WEBINAR
Please use this button to register in our system as a new user, or to purchase a CE Activity.
For free CE's, returning users can simply click the "TAKE TEST/EVALUATION" button on the right.
Please use this button when you have completed the CE Activity and are ready to take the quiz and complete the evaluation.

Load-Bearing Walls: Getting Cardiovascular Therapy Right the First Time -RECORDED WEBINAR

About this Course

This course is a recorded (home study version) of the Arthur E. Schwarting Symposium on April 17, 2026 . The theme was "Measure Twice, Cut Once: A Carpentry Approach to Pharmacy."

 

Learning Objectives

Upon completion of this application based CE Activity, a pharmacist will be able to:

  • Identify high-risk cardiovascular medications that are most commonly associated with preventable adverse drug events amid transitions of care
  • Describe evidence-based principles for precise cardiovascular medication dosing, including clinically relevant pharmacokinetic considerations that influence drug and dose selection
  • Explain the benefits and limitations of clinical decision support tools in cardiovascular pharmacotherapy
  • Recognize common system-level and cognitive factors contributing to cardiovascular medication near misses and adverse effects

Release and Expiration Dates

Released:  April 17, 2026
Expires:  April 17, 2029

Course Fee

$10 Pharmacist

ACPE UAN

0009-0000-26-009-H01-P

Session Code

26RS09-RHA98

Accreditation Hours

1 hour of CE (0.1 CEUs)

Additional Information

 

How to Complete Evaluation:  When you are ready to submit posttest answers, go to the BLUE take test/evaluation button. Use the session code from your confirmation email or from the box above, not from the end of the video!

Accreditation Statement

The University of Connecticut School of Pharmacy and Pharmaceutical Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this knowledge-based activity and will receive up to 1 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-26-009-H01-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

Katelyn Galli, PharmD, BCCP

Assistant Clinical Professor

University of Connecticut School of Pharmacy and Pharmaceutical Sciences

Storrs, CT

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy and Pharmaceutical Sciences requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

  • Katelyn Galli has no relationships with ineligible companies

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy and Pharmaceutical Sciences or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

CONTENT

Posttest

1. Which of the following medications would be considered high risk for error during the medication reconciliation process? 

  1. Apixaban
  2. Citalopram
  3. Fexofenadine

2. Upon daily chart review, you identify that Jack has an AKI and review his medications for necessary adjustments. Which of the following is most appropriate regarding his apixaban?

  1. Continue to hold anticoagulation given increased bleeding risk
  2. Stop apixaban and start rivaroxaban 15mg daily instead
  3. Consider transitioning to heparin via aPTT measurement until AKI resolves

3. The team decides to start Jack on oral amiodarone 400mg TID x 3 days, 200 mg TID x 3 days, then 200 mg daily. Which of the following is most important for the pharmacist to ensure at discharge?

  1. Ensure the prescription is sent to the patient's home pharmacy for easy refills
  2. Confirm that thyroid function tests are ordered and assessed before starting the amiodarone
  3. Suggest starting sotalol instead for better rate control

4. Which strategy can optimize clinical decision support for high-risk cardiac medications? 

  1. Prevent ordering of any anticoagulant except apixaban to ensure standardization
  2. Integrate most recent SCr values and dosing recommendations into sotalol orders
  3. Block order entry of amiodarone by prescribers if all baseline labs are not checked

5. The Epic medical record has the advantage of having access from outside health systems. The VAMC has a secure medical record that cannot be accessed. Jack gets most of his care and his medications at the VA. Which of the following factors increases his risk for experiencing medication errors?

  1. Fragmented medical records
  2. Use of a single pharmacy
  3. Poor insurance coverage

6. Jack's SCr is stable but remains elevated. Following diuresis, he is found to be cachectic and euvolemic with a “dry" weight of 58 kg. You recommend decreasing his apixaban to 2.5 mg BID but receive pushback from the provider as "this was his home dose." What kind of bias does this reflect?

  1. Anchoring bias
  2. Automation bias
  3. Availability bias

     

     

    VIDEO